RU2006126078A - Детектирование cd20 в терапии аутоиммунных заболеваний - Google Patents
Детектирование cd20 в терапии аутоиммунных заболеваний Download PDFInfo
- Publication number
- RU2006126078A RU2006126078A RU2006126078/13A RU2006126078A RU2006126078A RU 2006126078 A RU2006126078 A RU 2006126078A RU 2006126078/13 A RU2006126078/13 A RU 2006126078/13A RU 2006126078 A RU2006126078 A RU 2006126078A RU 2006126078 A RU2006126078 A RU 2006126078A
- Authority
- RU
- Russia
- Prior art keywords
- sample
- patient
- antibody
- autoimmune disease
- detected
- Prior art date
Links
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 title claims 8
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 title claims 8
- 208000023275 Autoimmune disease Diseases 0.000 title claims 6
- 238000001514 detection method Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims 19
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 4
- 238000001574 biopsy Methods 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 210000001165 lymph node Anatomy 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 229940123494 CD20 antagonist Drugs 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 238000001839 endoscopy Methods 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 210000001179 synovial fluid Anatomy 0.000 claims 1
- 210000001258 synovial membrane Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (19)
1. Способ лечения аутоиммунного заболевания у пациента, включающий в себя
(a) детектирование CD20 в образце, полученном из огранизма пациента; и
(b) если в образце детектируется CD20, введение CD20-антагониста пациенту в количестве, эффективном для лечения аутоиммунного заболевания.
2. Способ по п.1, согласно которому антагонист содержит антитело.
3. Способ по п.2, согласно которому антитело не конъюгировано с цитотоксическим агентом.
4. Способ по п.2, согласно которому антитело содержит ритуксимаб.
5. Способ по п.2, согласно которому антитело содержит гуманизированное [антитело] 2H7.
6. Способ по п.2, согласно которому антитело конъюгировано с цитотоксическим агентом.
7. Способ по п.1, согласно которому пациент страдает ревматоидным артритом.
8. Способ по п.7, согласно которому образец получен при биопсии [тканиU синовиума или синовиальной жидкости.
9. Способ по п.1, согласно которому пациент страдает волчанкой.
10. Способ по п.9, согласно которому образец представляет собой образец биопсии лимфатического узла, биопсии костного мозга или мононуклеарные клетки периферической крови (PBMC).
11. Способ по п.1, согласно которому пациент страдает язвенным колитом или воспалительным заболеванием кишечника (IBD).
12. Способ по п.11, согласно которому образцом является образец, полученный при эндоскопии.
13. Способ по п.1, согласно которому пациент страдает дерматологическим заболеванием или имеет дерматологическое проявление аутоиммунного заболевания.
14. Способ по п.13, согласно которому заболевание выбрано из группы, состоящей из псориаза, обыкновенной пузырчатки, ревматоидного артрита, волчанки и васкулита.
15. Способ по п.13, согласно которому образец представляет собой образец трепанобиопсии, мононуклеарные клетки периферической крови (PBMC) или образец [ткани] лимфатического узла.
16. Способ по п.1, который, по существу, состоит во введении антагониста млекопитающему.
17. Способ по п.1, согласно которому белок CD20 детектируют на стадии (a).
18. Способ по п.1, согласно которому нуклеиновую кислоту CD20 детектируют на стадии (a).
19. Способ лечения аутоиммунного заболевания у пациента, включающий в себя
(a) детектирование CD20-положительных В-клеток в образце, полученном из огранизма пациента; и
(b) если в образце детектируются CD20-положительные В-клетки, введение CD20-антитела пациенту в количестве, эффективном для лечения аутоиммунного заболевания.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53136303P | 2003-12-19 | 2003-12-19 | |
| US60/531,363 | 2003-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006126078A true RU2006126078A (ru) | 2008-01-27 |
Family
ID=34710220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006126078/13A RU2006126078A (ru) | 2003-12-19 | 2004-12-07 | Детектирование cd20 в терапии аутоиммунных заболеваний |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20050186206A1 (ru) |
| EP (1) | EP1696955A2 (ru) |
| JP (1) | JP2007514787A (ru) |
| KR (2) | KR20060109494A (ru) |
| CN (1) | CN1917901A (ru) |
| AU (2) | AU2004305560A1 (ru) |
| BR (1) | BRPI0417105A (ru) |
| CA (1) | CA2549122A1 (ru) |
| MX (1) | MXPA06006864A (ru) |
| RU (1) | RU2006126078A (ru) |
| WO (1) | WO2005060999A2 (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020027311A (ko) | 1999-05-07 | 2002-04-13 | 제넨테크, 인크. | Ｂ 세포 표면 마커에 결합하는 길항물질을 이용한자가면역 질환의 치료 |
| CN1592645A (zh) * | 2000-09-18 | 2005-03-09 | 拜奥根Idec公司 | 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法 |
| ME01775B (me) * | 2003-11-05 | 2011-02-28 | Glycart Biotechnology Ag | Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| AR053579A1 (es) * | 2005-04-15 | 2007-05-09 | Genentech Inc | Tratamiento de la enfermedad inflamatoria intestinal (eii) |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| EP1806365A1 (en) * | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| TW201438738A (zh) | 2008-09-16 | 2014-10-16 | Genentech Inc | 治療進展型多發性硬化症之方法 |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| JP5828151B6 (ja) | 2009-01-06 | 2018-09-19 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | アテローム性動脈硬化の処置のためのｂ細胞枯渇剤 |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| US9173961B2 (en) | 2010-02-10 | 2015-11-03 | Immunogen, Inc. | CD20 antibodies and uses thereof |
| GB201400442D0 (en) * | 2014-01-10 | 2014-02-26 | Sigmoid Pharma Ltd | Compositions for use in the treatment of ulcerative colitis |
| AR104368A1 (es) | 2015-04-03 | 2017-07-19 | Lilly Co Eli | Anticuerpos biespecíficos anti-cd20- / anti-baff |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5506126A (en) * | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
| US4861579A (en) * | 1988-03-17 | 1989-08-29 | American Cyanamid Company | Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies |
| US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| ES2091684T3 (es) * | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| US7744877B2 (en) * | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
| US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| WO1999002567A2 (en) * | 1997-07-08 | 1999-01-21 | Board Of Regents, The University Of Texas System | Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
| US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6242195B1 (en) * | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| JP2002522511A (ja) * | 1998-08-11 | 2002-07-23 | アイデック ファーマスーティカルズ コーポレイション | 抗ｃｄ２０抗体の投与を含むｂ細胞リンパ腫の併用療法 |
| US6224866B1 (en) * | 1998-10-07 | 2001-05-01 | Biocrystal Ltd. | Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors |
| EP1035172A3 (en) * | 1999-03-12 | 2002-11-27 | Fuji Photo Film Co., Ltd. | Azomethine compound and oily magenta ink |
| KR20020027311A (ko) * | 1999-05-07 | 2002-04-13 | 제넨테크, 인크. | Ｂ 세포 표면 마커에 결합하는 길항물질을 이용한자가면역 질환의 치료 |
| WO2000074718A1 (en) * | 1999-06-09 | 2000-12-14 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| DE19930748C2 (de) * | 1999-07-02 | 2001-05-17 | Infineon Technologies Ag | Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip |
| US20020006404A1 (en) * | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| US20030185796A1 (en) * | 2000-03-24 | 2003-10-02 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma |
| EP1283722A1 (en) * | 2000-03-31 | 2003-02-19 | Idec Pharmaceuticals Corporation | Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma |
| DK1272647T3 (en) * | 2000-04-11 | 2014-12-15 | Genentech Inc | Multivalent antibodies and uses thereof |
| MXPA02010507A (es) * | 2000-04-25 | 2003-05-14 | Idec Pharma Corp | Administracion intratecal de rituximab para el tratamiento de linfomas del sistema nervioso central. |
| US7534772B2 (en) * | 2000-06-22 | 2009-05-19 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
| CN1592645A (zh) * | 2000-09-18 | 2005-03-09 | 拜奥根Idec公司 | 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法 |
| US20030103971A1 (en) * | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
| WO2002078766A2 (en) * | 2001-04-02 | 2002-10-10 | Genentech, Inc. | Combination therapy |
| US7405047B2 (en) * | 2001-06-25 | 2008-07-29 | Phadia Ab | Method for estimation of the amount of specific cell types |
| JP4424987B2 (ja) * | 2001-09-20 | 2010-03-03 | ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム | Ｅｌｉｓａアッセイを用いた循環する治療抗体、抗原および抗原／抗体複合体の測定 |
| ATE430580T1 (de) * | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| CN100522999C (zh) * | 2002-02-14 | 2009-08-05 | 免疫医疗公司 | 抗cd20抗体及其融合蛋白和使用方法 |
| US20030219818A1 (en) * | 2002-05-10 | 2003-11-27 | Bohen Sean P. | Methods and compositions for determining neoplastic disease responsiveness to antibody therapy |
-
2004
- 2004-12-07 CA CA002549122A patent/CA2549122A1/en not_active Abandoned
- 2004-12-07 WO PCT/US2004/040949 patent/WO2005060999A2/en not_active Ceased
- 2004-12-07 KR KR1020067012188A patent/KR20060109494A/ko not_active Ceased
- 2004-12-07 MX MXPA06006864A patent/MXPA06006864A/es not_active Application Discontinuation
- 2004-12-07 BR BRPI0417105-5A patent/BRPI0417105A/pt not_active IP Right Cessation
- 2004-12-07 KR KR1020097006697A patent/KR20090036154A/ko not_active Withdrawn
- 2004-12-07 EP EP04813284A patent/EP1696955A2/en not_active Withdrawn
- 2004-12-07 CN CNA2004800419170A patent/CN1917901A/zh active Pending
- 2004-12-07 JP JP2006545726A patent/JP2007514787A/ja active Pending
- 2004-12-07 US US11/005,677 patent/US20050186206A1/en not_active Abandoned
- 2004-12-07 RU RU2006126078/13A patent/RU2006126078A/ru not_active Application Discontinuation
- 2004-12-07 AU AU2004305560A patent/AU2004305560A1/en not_active Abandoned
-
2009
- 2009-05-15 AU AU2009201932A patent/AU2009201932A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009201932A1 (en) | 2009-06-04 |
| MXPA06006864A (es) | 2006-08-23 |
| CA2549122A1 (en) | 2005-07-07 |
| WO2005060999A2 (en) | 2005-07-07 |
| EP1696955A2 (en) | 2006-09-06 |
| KR20090036154A (ko) | 2009-04-13 |
| AU2004305560A1 (en) | 2005-07-07 |
| US20050186206A1 (en) | 2005-08-25 |
| CN1917901A (zh) | 2007-02-21 |
| WO2005060999A3 (en) | 2006-01-26 |
| BRPI0417105A (pt) | 2007-02-06 |
| JP2007514787A (ja) | 2007-06-07 |
| KR20060109494A (ko) | 2006-10-20 |
| WO2005060999A9 (en) | 2008-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006126078A (ru) | Детектирование cd20 в терапии аутоиммунных заболеваний | |
| Escribano et al. | Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications | |
| ATE283289T1 (de) | Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten | |
| CA3189109A1 (en) | Methods and systems for cell-free dna fragment size densities to assess cancer | |
| US20170105971A1 (en) | Methods and compounds for the treatment of bone loss and/or pain | |
| Pablos et al. | Clonally expanded lymphocytes in the minor salivary glands of Sjögren's syndrome patients without lymphoproliferative disease | |
| Chen et al. | Accuracy of immunochemical fecal occult blood test for detecting colorectal neoplasms in individuals undergoing health check-ups | |
| Girard et al. | Subcutaneous phaeohyphomycosis due to Pyrenochaeta romeroi in a patient with leprosy | |
| Komatsuda et al. | Cutaneous polyarteritis nodosa in a patient with Crohn’s disease | |
| Larsson et al. | Localization of various plasma proteins in the skin in rheumatoid arthritis: an immunofluorescent microscopic study of skin biopsies | |
| Falkenberg et al. | Kidney-derived urinary antigens assayed with monoclonal antibodies for the detection of renal damage | |
| Guillot et al. | Detection of antibodies to Aspergillus fumigatus in serum of horses with mycosis of the auditory tube diverticulum (guttural pouch) | |
| Tahvildar | Toxocariasis antibody tittering in patients with uveitis | |
| Mahmood et al. | Psoriatic arthritis: A review | |
| Zhao et al. | IDDF2023-ABS-0211 Highly immunoglobulin a/g/m-coated gut microbial consortia in inflammatory bowel disease | |
| Makhlouf et al. | Serum angiopoietin-2 as a noninvasive diagnostic marker of stages of liver fibrosis in chronic hepatitis C patients | |
| Permin et al. | Deposits of plasma proteins in the skin during treatment with carbamazepine and diphenylhydantoin | |
| Brugge | Fine needle aspiration of pancreatic masses: the clinical impact | |
| ATE347696T1 (de) | Verfahren zur diagnose von chronisch entzündlichen darmerkrankungen | |
| RU96113025A (ru) | Способ определения послеоперационной кровопотери | |
| Borel et al. | Comparison of a digestion-sedimentation technique with the Kato-Katz technique in the detection and quantification of S. mansoni eggs in light to moderate infections | |
| Marks et al. | Defining immune cell phenotypes that distinguish treatment responders and non-responders in RA | |
| Andrés et al. | OP0128 A PROTEOMIC ANALYSIS OF SUBCLINICAL SYNOVIAL INFLAMMATION ASSOCIATED WITH MONOSODIUM URATE CRYSTAL DEPOSITION | |
| Ajetunmobi et al. | Immunohistochemical profiling of lymphomas in Jos University Teaching Hospital. Jos | |
| TW200507828A (en) | Method for treatment of chemotherapy-induced diarrhea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080610 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20090515 |
|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100128 |